5 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $-2.12 | $-1.97 | +7.3% | Beat |
| Q1 2026 | 2026-03-31 | $-4.04 | $-3.40 | +15.8% | Beat |
| Q4 2025 | 2025-12-31 | $-2.70 | $-2.11 | +21.7% | Beat |
| Q3 2025 | 2025-09-30 | $-2.15 | $-0.51 | +76.3% | Beat |
| Q2 2025 | 2025-06-30 | $-3.03 | $-2.13 | +29.6% | Beat |
Earnings Beat Rate
Moderna has beaten analyst EPS estimates in 5 of 5 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →